

Robert J Chilton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7274180/publications.pdf>

Version: 2024-02-01

57
papers

1,266
citations

471061

17
h-index

377514

34
g-index

64
all docs

64
docs citations

64
times ranked

2049
citing authors

#	ARTICLE	IF	CITATIONS
1	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016, 39, 717-725.	4.3	244
2	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	4.3	109
3	Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 137-143.	1.0	101
4	The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. <i>Current Cardiology Reports</i> , 2020, 22, 53.	1.3	93
5	Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide-1-Based Therapies. <i>American Journal of Medicine</i> , 2011, 124, S35-S53.	0.6	59
6	Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. <i>Clinical Therapeutics</i> , 2003, 25, B4-B31.	1.1	54
7	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	4.3	45
8	Infection of an Implantable Cardioverter Defibrillator: Management Without Removal of the Device in Selected Cases. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990, 13, 1352-1355.	0.5	38
9	Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 80.	1.2	38
10	Applications of miRNA Technology for Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2014, 16, 386.	2.0	37
11	Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1620-1624.	2.2	36
12	Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 81-86.	1.0	34
13	Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 16-29.	2.2	32
14	Real-world evidence and product development: Opportunities, challenges and risk mitigation. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 840-846.	1.0	27
15	GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects. <i>Current Atherosclerosis Reports</i> , 2009, 11, 93-99.	2.0	24
16	Vasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 123-128.	2.0	21
17	EMPA-REG OUTCOME: The Cardiologist's Point of View. <i>American Journal of Cardiology</i> , 2017, 120, S53-S58.	0.7	18
18	Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 786-799.	2.2	18

#	ARTICLE	IF	CITATIONS
19	SGLT2 inhibitors: a narrative review of efficacy and safety. <i>Journal of Osteopathic Medicine</i> , 2021, 121, 229-239.	0.4	18
20	Pathophysiology of coronary heart disease: a brief review. <i>Journal of the American Osteopathic Association</i> , The, 2004, 104, S5-8.	1.7	18
21	Cardiac Manifestations of Congenital Generalized Lipodystrophy. <i>Clinical Diabetes</i> , 2016, 34, 181-186.	1.2	16
22	Diabetes and stroke: An important complication. <i>Journal of Diabetes</i> , 2021, 13, 184-190.	0.8	16
23	Acute directional coronary atherectomy prior to stenting in complex coronary lesions: ADAPTS study. , 1998, 45, 105-112.		14
24	EMPA-REG OUTCOME: The Cardiologist's Point of View. <i>American Journal of Medicine</i> , 2017, 130, S57-S62.	0.6	13
25	Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, 10, 3-13.	0.5	13
26	Integrative Computational and Experimental Approaches to Establish a Post-Myocardial Infarction Knowledge Map. <i>PLoS Computational Biology</i> , 2014, 10, e1003472.	1.5	10
27	Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00034.	1.0	9
28	Targeting myocardial infarction-specific protein interaction network using computational analyses. , 2011, , .		8
29	Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 551-564.	1.2	7
30	The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 144.	1.7	7
31	Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials. <i>Journal of Diabetes</i> , 2020, 12, 279-293.	0.8	7
32	Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes. <i>Primary Care Diabetes</i> , 2020, 14, 193-212.	0.9	7
33	Thiazolidinediones and cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2005, 7, 115-120.	2.0	6
34	Statin therapy in cardiovascular diseases other than atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2007, 9, 25-32.	2.0	6
35	Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00014.	1.0	6
36	A new perspective on lowering CV risk from hypoglycaemia. <i>European Heart Journal</i> , 2020, 41, 218-220.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors. <i>Heart Failure Reviews</i> , 2021, 26, 643-652.	1.7	6
38	PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 840-854.	0.6	6
39	Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 603-611.	0.9	5
40	Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era. <i>Cardiovascular Endocrinology and Metabolism</i> , 2018, 7, 2-3.	0.5	5
41	A Cardiologist's View of Hypoglycemia. <i>Current Atherosclerosis Reports</i> , 2010, 12, 88-95.	2.0	4
42	Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes. <i>European Endocrinology</i> , 2014, 10, 117.	0.8	3
43	Aggressive medical management of coronary artery disease versus mechanical revascularization. <i>Current Atherosclerosis Reports</i> , 2003, 5, 118-123.	2.0	2
44	Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists. <i>Journal of Diabetes & Metabolism</i> , 2015, 06, .	0.2	2
45	Lipids as risk markers for type 2 diabetes. <i>Journal of Diabetes</i> , 2019, 11, 176-178.	0.8	2
46	Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 219-234.	1.7	2
47	Lipid and nonlipid benefits of statins. <i>Journal of the American Osteopathic Association</i> , The, 2003, 103, S12-7.	1.7	2
48	Myocardial considerations in type 2 diabetes: 2018. <i>Journal of Diabetes</i> , 2018, 10, 784-788.	0.8	1
49	The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 143-152.	0.5	1
50	Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 345-349.	1.2	0
51	PCSK9 inhibitors and diabetes: Translational biology to clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 451-453.	2.2	0
52	A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 36-41.	0.5	0
53	The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1221-1229.	0.7	0
54	Beyond the myocardium: Sodium-glucose cotransporter 2 inhibitors in heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1215-1218.	2.2	0

#	ARTICLE	IF	CITATIONS
55	The new "lower is better" lipid goals: are they achievable with today's drugs?. Journal of the American Osteopathic Association, The, 2002, 102, S1-5.	1.7	0
56	Coadministration therapy in hypercholesterolemia: a novel approach to achieving lipid goals--introduction. Journal of the American Osteopathic Association, The, 2004, 104, S3-4.	1.7	0
57	Current and Emerging Issues in the Management of Heart Failure in Primary Care. Journal of Family Practice, 2020, 69, S27-S32.	0.2	0